Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318318 | 1.00 | BCHE (0.46) | BCHEALDH1A1SLC6A12GAASMN1; SMN2 | |
| SCHEMBL6315785 | 0.93 | SMN1; SMN2 (0.39) | BCHEALDH1A1GAASMN1; SMN2 | |
| SCHEMBL6315793 | 0.93 | SMN1; SMN2 (0.39) | BCHEALDH1A1GAASMN1; SMN2 | |
| SCHEMBL6323037 | 0.92 | ALDH1A1 (0.38) | BCHEALDH1A1SLC6A12 | |
| SCHEMBL6323034 | 0.92 | ALDH1A1 (0.38) | BCHEALDH1A1SLC6A12 | |
| SCHEMBL6325265 | 0.89 | SLC6A12 (0.38) | BCHEALDH1A1SLC6A12 | |
| SCHEMBL6325272 | 0.89 | SLC6A12 (0.38) | BCHEALDH1A1SLC6A12 | |
| SCHEMBL6317028 | 0.84 | CYP1A2 (0.42) | SIGMAR1 | |
| SCHEMBL6317022 | 0.84 | CYP1A2 (0.42) | SIGMAR1 | |
| SCHEMBL6316624 | 0.79 | CYP1A2 (0.38) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| CN-1870967-A | Hair conditioning composition | UNILEVER NV (NL) | 2006-11-29 | — | — | CN | disclosed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-6866383-B2 | Topcoat compositions, substrates containing a topcoat derived therefrom, and methods of preparing the same | AVERY DENNISON CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
| CN-1553853-A | Topcoat compositions, substrates containing a topcoat derived therefrom, and methods of preparing the same | 艾弗里・丹尼森公司 | 2004-12-08 | — | — | CN | disclosed |
| EP-1419048-A4 | TOPCOAT COMPOSITIONS, SUBSTRATES CONTAINING A TOPCOAT DERIVED THEREFROM, AND METHODS OF PREPARING THE SAME | AVERY DENNISON CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1419048-A1 | TOPCOAT COMPOSITIONS, SUBSTRATES CONTAINING A TOPCOAT DERIVED THEREFROM, AND METHODS OF PREPARING THE SAME | AVERY DENNISON CORPORATION (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
| US-20030112311-A1 | Topcoat compositions, substrates containing a topcoat derived therefrom, and methods of preparing the same | AVERY DENNISON CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003016045-A1 | TOPCOAT COMPOSITIONS, SUBSTRATES CONTAINING A TOPCOAT DERIVED THEREFROM, AND METHODS OF PREPARING THE SAME | AVERY DENNISON CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0771670-B1 | Mordanting substrates and agents | IRIS GRAPHICS INC (US) | 2002-02-20 | — | — | EP | disclosed |
| US-6093447-A | MAKING A SUBSTRATE FOR PRINTING SUCH AS INK JET PRINTING BY INCORPORATING INTO A POROUS SUBSTRATE A MORDANTING AGENT COMPRISING A MIXTURE OF A PHOSPHOLIPID AND A POLYQUATERNARY CELLULOSIC POLYMER; IMMOBILIZATION OF DYE; NO DOT SPREADING | IRIS GRAPHICS, INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0771670-A1 | Mordanting substrates and agents | IRIS GRAPHICS, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | BCHE 1667/4885ALDH1A1 245/4885SLC6A12 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.